Cell-Based Assays Using Differentiated Human Induced Pluripotent Cells
Zameel Cader1, Martin Graf2, Mark Burcin2
1Translational Molecular Neuroscience Group, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Abstract:
This chapter describes the requirements and preconditions for using human induced pluripotent cell lines in assay development within the pharmaceutical industry. The joint collaborative effort between academic and pharma partners within the StemBANCC consortium which enabled the implementation of iPSC-derived cellular models for drug discovery is highlighted. This large collaborative scientific network has successfully derived a significant number of well-characterized patient-specific iPSC lines and established disease-relevant cellular assays, both of which are requirements for enabling pharmaceutical companies to develop more efficacious and safer medicines.
Related Concept Videos
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
iPS Cell Differentiation
Differentiation of Common Myeloid Progenitor Cells
Embryonic Stem Cells


